A 19-year-old Stanford dropout walking into rooms with Henry Kissinger, two former US Secretaries of State, and Oracle's Larry Ellison. She is pitching a machine that can run hundreds of medical tests from a single drop of blood, cheaper than any lab in America. No needles. Results in hours. She calls it Edison.
They all say yes.
By 2014, her company, Theranos, is worth $9 billion. She is on the cover of Forbes as the youngest self-made female billionaire. The Wall Street Journal calls her the next Steve Jobs.
But…. the machine does not work.
How it started
Elizabeth Holmes dropped out of Stanford in 2003 after filing a patent for a drug-delivery patch. The patch never made it anywhere, but the obsession stuck. She wanted to change how healthcare worked. She believed that if people could test their own blood easily and cheaply, they would catch diseases earlier and live longer.
The mission was real. The technology was never ready.
Theranos built a device called Edison that was supposed to run up to 240 tests from a finger-prick blood sample. Holmes raised over $400 million by 2014 on the strength of this promise. Walgreens partnered with Theranos in 2013 to roll out testing centers in their stores across America. Real patients were getting real results. Or so everyone thought.
Behind the curtain, the Edison machine was producing wildly inaccurate results. Theranos knew it. So they quietly started running most of their tests on standard Siemens machines that any other lab would use while still telling investors, patients, and partners that Edison was doing the work.
That discrepancy between what they said they had and what they actually had was the fraud.
The walls close in
Wall Street Journal reporter John Carreyrou, a two-time Pulitzer Prize winner, started quietly talking to Theranos employees in 2015. What he heard was very different from the public story. Former employees told him the results were inaccurate. Others confirmed the Siemens machines. His story ran in October 2015.
After that, everything moved fast. The SEC opened an investigation. The Centers for Medicare and Medicaid Services revoked Theranos's lab license. The company laid off over 40% of its staff. Forbes revised Holmes's net worth down to zero.
In 2018, Holmes and her co-founder Ramesh "Sunny" Balwani were charged with raising more than $700 million through fraud, according to the SEC. Holmes was convicted in January 2022 on four counts of fraud and sentenced to over 11 years in prison.
Theranos shut down in 2018, unable to find a buyer. Pretty tragic ending to a very hopeful story.
What founders can actually take from this
Most Theranos pieces stop at surface-level lessons. The real takeaways are a bit more uncomfortable.
The Silicon Valley playbook has a kill zone
Holmes lived inside a culture that celebrated "fake it till you make it." In software, that is often fine. Ship something rough, get feedback, improve. The stakes of getting it wrong are low. But Theranos was operating in healthcare, where getting a result wrong tells a breast cancer survivor her cancer has returned. That is a completely different game.
The lesson for founders is knowing which category your product falls into. Consumer app? You can iterate in public. Medical device? Financial advice? Infrastructure? The bar for shipping changes completely. Knowing early saves lives and legal fees.
A name-brand board is not a validation signal
Theranos had Kissinger, former defense secretaries, and well-known generals on its board. None of them had medical or scientific backgrounds. Holmes had also structured her voting rights so she held 99% of total voting power, which made the board functionally decorative.
Founders often treat a prestigious advisor list as proof of legitimacy. Ask what those advisors are actually reviewing. A board full of famous names in the wrong fields is a press release, not a check on your decisions.
Secrecy compounds mistakes
When Theranos employees raised concerns internally, they were threatened with lawsuits. The CFO was fired in 2006 for questioning the reliability of the lab equipment. Holmes and Balwani surrounded themselves entirely with people who would not push back.
This is a mistake founders make at every scale, not just at the Theranos level. When your culture punishes dissent, bad information stops rising to the top. You stop hearing about the thing that is actually broken until it is catastrophic. Healthy companies build in friction. They reward the person who says "this is not working" before the regulator does.
Momentum is a drug
By the time Theranos had the Walgreens partnership, the Forbes cover, and $400 million raised; the momentum had taken on a life of its own. Investors who might have asked harder questions felt social pressure to trust what everyone else trusted. Nobody wanted to be the person who killed the "female Steve Jobs" story.
Watch for the moment when people stop asking how the product works and start just celebrating that it exists. That is a big, big warning sign.
The product has to work
This sounds obvious. It is not. Holmes raised $700 million and built a company with hundreds of employees without a working product at its core. The technology was always aspirational. Founders can spend years fundraising, hiring, and expanding around a product that has not been validated. The discipline of proving the core thing works, before everything else is built around it, is harder than it sounds. But it is the only thing that eventually matters.
Theranos is a story about what happens when the pressure to appear successful becomes stronger than the discipline to stay honest about where you actually are.
Holmes was not unusual in wanting to change the world. She was unusual in how far she went when the gap between ambition and reality opened up.
Every founder carries some version of that gap. The ones who survive it are the ones who keep it honest.
If this was useful, send it to one person building something. That's how Read Startup grows.
